Seven Eight Capital, LP Immuno Gen, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$14.09 - $19.87 $2 Million - $2.82 Million
141,946 Added 146.36%
238,930 $3.79 Million
Q2 2023

Aug 14, 2023
BUY
$3.75 - $20.05 $363,690 - $1.94 Million
96,984 New
96,984 $1.83 Million
Q3 2022

Nov 10, 2022
BUY
$4.48 - $6.47 $56,591 - $81,729
12,632 New
12,632 $60,000

Others Institutions Holding IMGN

# of Institutions
8
Shares Held
1.41M
Call Options Held
0
Put Options Held
0
View Full List

About ImmunoGen, Inc.

IMGN Quotes by TradingView
  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email